今天,你不能轻视任何一家Biotech,因为一旦达成BD就翻身。据医药魔方,2025H1,中国创新药License out总金额接近660亿美元,赶超2024全年BD交易总额。从2023年至2024年,肿瘤管线出海授权交易占比从72%下降至61%,而代谢和自免占比从12%提升至25%,未来将跻身主流方向。自信点,中国创新药在二代IO、ADC、CAR-T、血液瘤小分子领域,已取得领导地位。而MNC不...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.